CNS10-NPC / California Institute for Regenerative Medicine, Cedars-Sinai - LARVOL DELTA

CNS10-NPC for the Treatment of RP (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Cedars-Sinai Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Jul 2026 | Trial primary completion date: Nov 2025 ➔ Jul 2026

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

A Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa (ARVO 2025) - "Purpose This dose escalation Phase 1/2a study seeks to determine the safety of a single subretinal injection of a fetal cortical-derived human neural progenitor cell product (termed CNS10-NPC) in patients with retinitis pigmentosa (RP)...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Cataract • Inherited Retinal Dystrophy • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CNS10-NPC for the Treatment of RP (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Cedars-Sinai Medical Center | Trial completion date: Nov 2024 ➔ Nov 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

GMP-grade human neural progenitors delivered subretinally protect vision in rat model of retinal degeneration and survive in minipigs. (PubMed, J Transl Med) - P1 | "These extensive studies supported an approved IND and the translation of CNS10-NPC to an ongoing Phase 1/2a clinical trial (NCT04284293) for the treatment of retinitis pigmentosa."

Journal • Preclinical • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CNS10-NPC for the Treatment of RP (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Cedars-Sinai Medical Center | Trial completion date: Aug 2023 ➔ Nov 2024 | Trial primary completion date: Aug 2023 ➔ Nov 2024

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CNS10-NPC for the Treatment of RP (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Cedars-Sinai Medical Center; Trial completion date: Jun 2022 ➔ Aug 2023; Trial primary completion date: Apr 2022 ➔ Aug 2023

Clinical • Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CNS10-NPC for the Treatment of RP (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Cedars-Sinai Medical Center

Clinical • New P1 trial